Methylphenidate reduces mental fatigue and improves processing speed in persons suffered a traumatic brain injury

Brain Inj. 2015;29(6):758-65. doi: 10.3109/02699052.2015.1004747. Epub 2015 Mar 20.

Abstract

Objective: Post-traumatic brain injury symptoms, such as mental fatigue, have considerable negative impacts on quality-of-life. In the present study the effects of methylphenidate in two different dosages were assessed with regard to mental fatigue, pain and cognitive functions in persons who had suffered a traumatic brain injury.

Methods: Fifty-one subjects were included and 44 completed the study. The treatment continued for 12 weeks, including three treatment periods with no medication for 4 weeks, administration of low dose methylphenidate (up to 5 mg × 3) for 4 weeks and normal dose methylphenidate (up to 20 mg × 3) for a further 4 weeks. The patients were randomized into three groups where all groups were given all treatments.

Results: Significantly reduced mental fatigue, assessed with the Mental Fatigue Scale (MFS) and increased information processing speed (coding, WAIS-III), were detected. The SF-36 vitality and social functioning scales were also improved significantly. Pain was not reduced by methylphenidate. The positive effects of treatment were dose-dependent, with the most prominent effects being at 60 mg methylphenidate/day spread over three doses. Observed side-effects were increased blood pressure and increased heart rate.

Conclusions: Methylphenidate was generally well-tolerated and it improved long-lasting mental fatigue and processing speed after traumatic brain injury.

Keywords: Cognition; TBI; mental fatigue; methylphenidate; pain.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Brain Injuries / drug therapy*
  • Brain Injuries / psychology
  • Cognition / drug effects
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Male
  • Mental Fatigue / drug therapy*
  • Mental Fatigue / psychology
  • Methylphenidate / therapeutic use*
  • Middle Aged
  • Pain / drug therapy
  • Treatment Outcome

Substances

  • Methylphenidate